Its announcement comes after studies showed that young people who were given the vaccine were at increased risk of developing narcolepsy, which causes sufferers to fall asleep unexpectedly.
Pandemrix, manufactured by the British pharmaceutical giant GlaxoSmithKline, was given to 30million people across Europe after the outbreak of swine flu – the H1N1 strain of the virus - that started in Mexico early in 2009.
It was approved by the European regulator in September that year but by the following August its safety was being reviewed after health officials in Finland claimed it had been linked to narcolepsy.
In total 335 cases of the sleeping disorder in people vaccinated with Pandemrix have been reported to GSK, with 10 suspected cases out of the 6million doses given in Britain.
New guidelines for managing cholesterol call for more aggressive prevention and earlier treatment, including a recommendation...
